<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026662</url>
  </required_header>
  <id_info>
    <org_study_id>eMatrixCO2 Preab</org_study_id>
    <nct_id>NCT01026662</nct_id>
  </id_info>
  <brief_title>In-vivo Analysis of a Fractional CO2 Laser System (eMatrixCO2) Intended for Treatment of Soft Tissue</brief_title>
  <acronym>eMatrixCO2</acronym>
  <official_title>In-vivo Analysis of a Fractional CO2 Laser System (eMatrixCO2) Intended for Treatment of Soft Tissue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syneron Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Syneron Medical</source>
  <brief_summary>
    <textblock>
      This study will:

      Evaluate the in vivo effects of treatment with eMatrixCO2 and to determine the dynamics of
      their development over time following treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Histological and molecular assessment of tissue taken following treatment with different parameters and at various time points</measure>
    <time_frame>Immediate, 1, 3, 10, 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Record number and type of any AE during the study</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Abdominoplasty</condition>
  <arm_group>
    <arm_group_label>Abdominoplasty</arm_group_label>
    <description>Subjects scheduled for abdominoplasty surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation and skin resurfacing</intervention_name>
    <description>Subjects will receive treatment on the abdomen at different timepoints prior to a scheduled abdominoplasty. Following tissues excision samples of the treated tissue will be taken for analysis.</description>
    <arm_group_label>Abdominoplasty</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>eMatrixCO2</intervention_name>
    <arm_group_label>Abdominoplasty</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Abdominal Skin tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy Subjects scheduled for an abdominoplasty surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent agreement signed by the subject.

          -  Healthy males or females older than 21 to 60 years of age.

          -  Fitzpatrick skin type I-V (Although the systems are cleared for all skin types I-VI,
             it is recommended to use the Matrix applicators on skin types I - V).

          -  Willingness to follow the treatment and follow-up schedule and the post-treatment
             care.

          -  For female candidates - post-menopausal or surgically sterilized, or using a medically
             acceptable form of birth control at least 3 months prior to enrollment and during the
             entire course of the study (i.e., oral contraceptives, IUD, contraceptive implant,
             barrier methods with spermicide, or abstinence).

        Exclusion Criteria:

          -  Pregnant and/or breastfeeding.

          -  Having a history of diseases stimulated by heat, such as recurrent Herpes

          -  Simplex in the treated area, unless treatment is conducted following a prophylactic
             regimen.

          -  Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen-containing
             agents) one week before and after each treatment session.

          -  Use of retinoids, antioxidants or therapeutic skin nourishing supplements at medicinal
             concentration within 2 months of treatment or during the study and oral retinoids
             within 6 months of the study.

          -  Having received treatment with light, RF or other devices in the treated area within 6
             months of treatment or during the study.

          -  Having received collagen/fat injections or other methods of augmentation with injected
             or implanted material in the treated area within 9 months of treatment or during the
             study.

          -  Having received Botox in the treated area within 6 months of treatment or during the
             study.

          -  Having undergone any other surgery in the treated area within 6 months of treatment
             (or more if skin has not healed completely) or during the study.

          -  History of keloid scarring or of abnormal wound healing.

          -  Suffering from current or history of significant skin conditions in the treated area
             or inflammatory skin conditions, including, but not limited to: active acne, excessive
             skin dryness, psoriasis, eczema, rash, rosacea (particularly severe open wound stage),
             varicella scars, open lacerations or abrasions and active cold sores or herpes sores
             prior to treatment (duration of resolution as per the Investigator's discretion) or
             during the treatment course.

          -  History of immunosuppression/immune deficiency disorders (including HIV infection or
             AIDS) or currently using immunosuppressive medications.

          -  History of epidermal or dermal disorders (particularly if involving collagen or
             microvascularity).

          -  History of pigmentary disorders, particularly tendency for hyper- or
             hypo-pigmentation.

          -  Suffering from hormonal imbalance, as per the Investigator's discretion.

          -  Having a known anticoagulative or thromboembolic condition or taking anticoagulation
             medications one week prior to and during the treatment course (to allow inclusion,
             temporary cessation of use as per the subject's physician discretion).

          -  Having or undergoing any form of treatment for active cancer, or having a history of
             skin cancer or any other cancer in the areas to be treated, including actinic
             keratosis, presence of malignant or pre-malignant pigmented lesions.

          -  Suffering from significant concurrent illness, such as cardiac disorders, diabetes
             (type I or II), or pertinent neurological disorders.

        Vascular lesion, tattoo or permanent make-up in the treated area.

          -  Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning
             during the study.

          -  Participation in a study of another device or drug within three month prior to
             enrollment or during the study.

          -  As per the Investigator's discretion, any physical or mental condition which might
             make it unsafe for the subject to participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SouthWestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8843</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2009</study_first_submitted>
  <study_first_submitted_qc>December 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <last_update_submitted>November 28, 2014</last_update_submitted>
  <last_update_submitted_qc>November 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aesthetic dermatology</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

